Trials / Not Yet Recruiting
Not Yet RecruitingNCT06716918
Effect of Antenatal Corticosteroids on Neonatal Hypoglycemia
The Effect of Antenatal Corticosteroids Prior to Planned Cesarean Section in Early Term on Neonatal Hypoglycemia
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 188 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- —
Summary
Comparing the incidence of neonatal hypoglycemia in infants born to mothers who received antenatal corticosteroids to those who did not.
Detailed description
Antenatal corticosteroids (ACS) are widely used to enhance fetal lung maturation in pregnancies at risk of preterm birth. However, their role in early-term pregnancies (37 to 38 weeks gestation) prior to planned cesarean section has been gaining attention. Early-term neonates delivered by cesarean section are at an increased risk of respiratory complications, and studies have shown that ACS can reduce these risks by accelerating fetal lung development. The use of ACS in this population, however, has raised concerns about its potential effects on neonatal metabolic outcomes, particularly neonatal hypoglycemia. Neonatal hypoglycemia, a common metabolic disorder in the early postnatal period, is often associated with antenatal corticosteroid exposure. ACS may increase fetal insulin production by stimulating pancreatic beta cells, leading to an increased risk of hypoglycemia after birth. Research indicates that while ACS effectively reduces respiratory morbidity in early-term neonates, it may concurrently raise the risk of neonatal hypoglycemia. For instance, a meta-analysis found a significant association between ACS and an increased incidence of hypoglycemia in term and near-term infants. Given these findings, research is crucial to assess the balance of risks and benefits of ACS in early-term cesarean deliveries. While ACS appears to reduce respiratory complications, understanding its full impact on neonatal hypoglycemia will help guide its use in clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Corticosteroid Injection | Participants who have received antenatal corticosteroids (betamethasone or dexamethasone) prior to cesarean section as part of their prenatal care. |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2025-09-30
- Completion
- 2025-10-30
- First posted
- 2024-12-04
- Last updated
- 2024-12-04
Locations
1 site across 1 country: Egypt
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06716918. Inclusion in this directory is not an endorsement.